Sign In
Buy MREO
$0.334
-0.0052 (-1.53%)
At Close: Jun 03, 2026
Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
04:05pm, Thursday, 17'th Dec 2020
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx's existing bone franchise
LONDON and REDWOOD CITY, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company foc
Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development
07:05am, Monday, 23'rd Nov 2020
LONDON and REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company foc
Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020
07:00am, Monday, 16'th Nov 2020
LONDON and REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company foc
Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference
07:23am, Tuesday, 10'th Nov 2020
LONDON and REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company foc
Billionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks
07:30pm, Monday, 17'th Aug 2020
There are two sides to every coin. For penny stocks, or tickers that trade for less than $5 per share, this rings especially true. As some of the most divisive names on the Street, they are either met
IPO Update: iTeos Therapeutics Finalizes IPO Plan
01:31pm, Tuesday, 21'st Jul 2020
iTeos Therapeutics has filed to raise $151 million from an IPO of its common stock. The firm is developing treatments for solid tumors and other high prevalence cancer conditions.
iTeos Therapeutics Begins U.S. IPO Rollout
03:59pm, Thursday, 02'nd Jul 2020
iTeos Therapeutics has filed to raise $100 million in a U.S. IPO. The firm is developing drug candidates to treat solid tumors and other cancer indications. ITO
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointments
Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019
11:00am, Tuesday, 16'th Jun 2020
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced financial result
Mereo BioPharma Announces Completion of $70 Million Private Placement
11:00am, Thursday, 04'th Jun 2020
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) today announces the completion of a $70 million (£56 million) private placement (the “Fundraising”) with a number of new and existing U.S based
33 Stocks Moving in Thursday's Pre-Market Session
11:19am, Thursday, 16'th Apr 2020
Gainers
Soligenix, Inc (NASDAQ: SNGX) shares rose 95% to $2.73 in pre-market trading after the company reported an exclusive license deal for novel vaccine adjuvant from BTG...
Business Update and Directorate Change
12:00pm, Friday, 27'th Mar 2020
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on rare diseases, today provided a general business update, incl
Comparing Mereo BioPharma Group (NASDAQ:MREO) & Nektar Therapeutics (NASDAQ:NKTR)
07:20am, Thursday, 12'th Mar 2020
Mereo BioPharma Group (NASDAQ:MREO) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their
Compugen: TIGIT Is The New Black
06:03pm, Monday, 02'nd Mar 2020
The anti-TIGIT approach is considered to be a promising anti-cancer strategy. Compugen is developing COM902, its own anti-TIGIT antibody. Bristol-Myers Squi
